| Q64059351 | A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling |
| Q48770689 | Age-related changes in [3H]nimodipine and [3H]rolipram binding in the rat brain |
| Q48150686 | Alterations of second messenger systems in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle |
| Q48767950 | Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents |
| Q50088416 | Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme |
| Q46865467 | Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. |
| Q60473732 | Chronic treatment with the potential antidepressant drug rolipram: the effect on the behavioural responses to adrenergic and dopaminergic receptor agonists with some biochemical correlates |
| Q49149171 | Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase |
| Q51543511 | Dissociation of hypnotic-anesthetic actions of alpha 2 agonists from cyclic AMP in the rat. |
| Q45062300 | Effect of rolipram on relative 14C-deoxyglucose uptake in inflammatory lesions and skeletal muscle |
| Q35044270 | Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats |
| Q73458383 | Effects of chronic treatment with a cyclic AMP-selective phosphodiesterase inhibitor, rolipram, on excitatory amino acid neurotransmission systems in young and aged rat brains |
| Q48414281 | Effects of forskolin and cyclic nucleotides in animal models predictive of antidepressant activity: interactions with rolipram |
| Q51085423 | Effects of rolipram on the elevated plus-maze test in rats: a preliminary study. |
| Q52054265 | Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats. |
| Q44490783 | Enhancement of antidepressant potency by a potentiator of AMPA receptors |
| Q47097007 | Genistein attenuates isoflurane-induced neurotoxicity and improves impaired spatial learning and memory by regulating cAMP/CREB and BDNF-TrkB-PI3K/Akt signaling |
| Q33840263 | Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule |
| Q28535169 | Impaired spatial learning and memory after sevoflurane-nitrous oxide anesthesia in aged rats is associated with down-regulated cAMP/CREB signaling |
| Q28396586 | Inhibition of phosphodiesterase-4 decreases ethanol intake in mice |
| Q28354227 | Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor |
| Q33474429 | Local delivery of rolipram, a phosphodiesterase-4-specific inhibitor, augments bone morphogenetic protein-induced bone formation |
| Q44225333 | Melatonin alters behavior and cAMP levels in nucleus accumbens induced by cocaine treatment |
| Q34452308 | Molecular cloning and expression of a human phosphodiesterase 4C. |
| Q52024769 | Pentoxifylline improves learning and memory in glutamate-lesioned rats. |
| Q36071589 | Pharmacology of second messengers: a critical appraisal |
| Q33934955 | Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain |
| Q48093692 | Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases |
| Q42719378 | Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling |
| Q42610451 | Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats |
| Q48498567 | Procyanidins protects against oxidative damage and cognitive deficits after traumatic brain injury |
| Q41527389 | Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases |
| Q33580822 | Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus |
| Q48416088 | Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats |
| Q48350419 | Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes beta-adrenoceptor subsensitivity in rat cerebral cortex |
| Q42724290 | Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase |
| Q48827943 | Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear |
| Q42461221 | The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice |
| Q45934678 | The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens. |
| Q38801216 | The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice |
| Q44998208 | The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior induced by cues or heroin priming in rats |
| Q34600037 | The role of phosphodiesterases in schizophrenia : therapeutic implications. |
| Q51475470 | The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration. |
| Q45041139 | The type IV-specific phosphodiesterase inhibitor rolipram and its effect on hippocampal long-term potentiation and synaptic tagging. |